Table 6. Univariate analysis of progression-free survival according to specific clinical, molecular and anatomical variables.
| Variable | Events/Patients | Median PFS1 (months) | HR2 | 95% CI3 | P at univariate |
|---|---|---|---|---|---|
| Age (≤70 vs >70 years) | 15/16 vs 31/31 | 16 vs 16 | 1.29 | 0.71-2.34 | 0.37 |
| Gender (male vs female) | 26/27 vs 20/20 | 14 vs 20 | 0.86 | 0.48-1.53 | 0.57 |
| Localization of primary tumor (right vs left colon) | 24/24 vs 22/23 | 13 vs 19 | 1.70 | 0.94-3.09 | 0.0445 |
| Site of metastases (only lung vs only liver vs multiple sites) | 20/21 vs 6/6 vs 20/20 | 21 vs 13 vs 12 | 0.36 | 0.18-0.73 | 0.0014 |
| KRAS mutational status (mutated vs wild-type) | 18/18 vs 28/29 | 12 vs 18 | 2.02 | 1.02-3.97 | 0.0093 |
| Response to first-line chemotherapy (RC/RP vs SD/ PD) | 25/26 vs 21/21 | 21 vs 13 | 0.35 | 0.18-0.69 | <0.0001 |
| Response to first-line SRT (CMR/PMR vs SMD/PMD) | 20/20 vs 11/11 | 20 vs 13 | 0.43 | 0.17-1.05 | 0.0199 |
| Number of lesions (1-3 vs 4-5 vs 6-7) | 24/25 vs 15/15 vs 7/7 | 19 vs 16 vs 6 | 0.14 | 0.02-0.85 | <0.0001 |
PFS1= Progression-Free Survival; HR2 = Hazard Ratio; CI3 = Confidence Intervals.